UBS Group AG Grows Position in Ingevity Corporation $NGVT

UBS Group AG grew its stake in shares of Ingevity Corporation (NYSE:NGVT) by 12.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 173,394 shares of the company’s stock after buying an additional 19,471 shares during the period. UBS Group AG’s holdings in Ingevity were worth $10,261,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Segall Bryant & Hamill LLC increased its position in Ingevity by 1.2% during the third quarter. Segall Bryant & Hamill LLC now owns 1,298,661 shares of the company’s stock worth $71,673,000 after buying an additional 15,451 shares in the last quarter. Millennium Management LLC grew its position in shares of Ingevity by 1.3% in the third quarter. Millennium Management LLC now owns 1,189,524 shares of the company’s stock valued at $65,650,000 after purchasing an additional 15,562 shares during the period. Simcoe Capital Management LLC grew its position in shares of Ingevity by 49.4% in the third quarter. Simcoe Capital Management LLC now owns 933,455 shares of the company’s stock valued at $51,517,000 after purchasing an additional 308,520 shares during the period. Maple Rock Capital Partners Inc. grew its position in shares of Ingevity by 3.2% in the third quarter. Maple Rock Capital Partners Inc. now owns 674,716 shares of the company’s stock valued at $37,238,000 after purchasing an additional 21,200 shares during the period. Finally, Harvey Partners LLC grew its position in shares of Ingevity by 5.1% in the third quarter. Harvey Partners LLC now owns 601,000 shares of the company’s stock valued at $33,169,000 after purchasing an additional 28,953 shares during the period. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Wall Street Analyst Weigh In

NGVT has been the subject of a number of recent analyst reports. Wall Street Zen raised Ingevity from a “hold” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company lifted their price objective on Ingevity from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Ingevity in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ingevity in a research report on Tuesday, April 21st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $83.00 price objective on shares of Ingevity in a research report on Monday, March 2nd. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $80.00.

Ingevity Price Performance

Shares of Ingevity stock opened at $67.50 on Friday. The business’s fifty day moving average price is $71.36 and its 200 day moving average price is $64.75. The stock has a market capitalization of $2.35 billion, a P/E ratio of -19.01 and a beta of 1.24. Ingevity Corporation has a twelve month low of $39.74 and a twelve month high of $79.29. The company has a current ratio of 1.42, a quick ratio of 0.92 and a debt-to-equity ratio of 27.83.

Ingevity (NYSE:NGVT) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.31. The company had revenue of $258.00 million for the quarter, compared to analysts’ expectations of $254.73 million. Ingevity had a positive return on equity of 207.82% and a negative net margin of 10.55%.The firm’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.01 earnings per share. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. As a group, research analysts anticipate that Ingevity Corporation will post 5.05 earnings per share for the current year.

Ingevity Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.